<DOC>
	<DOCNO>NCT02325414</DOCNO>
	<brief_summary>The overall objective study define effective therapeutic approach , use currently available medication , prevent mitigate loss bone mass bone strength occur acute spinal cord injury .</brief_summary>
	<brief_title>Prevention Bone Loss After Acute SCI Zoledronic Acid</brief_title>
	<detailed_description>This randomize , double-blind placebo-controlled study zoledronic acid evaluate efficacy safety 2 year period prevention bone loss maintenance bone strength individual recent onset SCI ( see diagram ) . Subjects randomize baseline visit receive either zoledronic acid placebo . At end first year study , treatment group re-randomized either zoledronic acid placebo evaluate durability response zoledronic acid utility serum bone marker guide therapeutic decision making . DXA imaging , CT image bone marker obtain baseline , 3 month , 6 month , 12 month , 18 month 24 month .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Bone Density Conservation Agents</mesh_term>
	<criteria>Inpatient Rehabilitation Institute Chicago ( RIC ) outpatient recently discharge RIC Males females Age &gt; /=18 year Medically stable opinion subject 's physiatrist SCI within 120 day inclusive time screen SCI inability ambulate independently ASIA Impairment Scale ( AIS ) A , B , C , time study entry Capable positioning DXA perform Able tolerate acetaminophen No known endocrinopathies ( diabetes type 1 2 include ) Normal TSH level Normal 25OH vitamin D level ( &gt; /= 20 ng/ml ) baseline ( subject may replete ) Normal calcium level Normal renal function ( creatinine &lt; 2.0 mg/dl ) Well hydrate adequate intake liquid Able return followup visit Capable read understanding inform consent document Males females childbearing potential must willing able use double barrier method contraception 2 month receive study drug Have Paget 's disease bone Malignancy cause acute SCI Have unexplained high level alkaline phosphatase blood Any active gastrointestinal condition result malabsorption Poor dental hygiene requirement invasive dental procedure within two month prior enrollment History bone metastasis skeletal malignancy History alcoholism drug abuse within 2 year prior study screen Other medical condition opinion investigator would preclude subject complete study Elevated liver function test &gt; 2x normal Currently prescribe anticonvulsant dose frequency determine interfere bone metabolism determine investigator Currently prescribe glucocorticoid , inhale glucocorticoid Current recent use boneactive agent , include bisphosphonate , raloxifene , hormone therapy ( estrogen estrogen/progestin ) , calcitonin strontiumcontaining compound within 60 day screen . Pregnant , plan become pregnant , lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Spinal Cord Injury</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Metabolic Bone Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Spinal Cord Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Nervous System</keyword>
	<keyword>Wounds Injuries</keyword>
	<keyword>Bone Density Conservation Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Department Defense</keyword>
</DOC>